WO2024163641A3 - Formulations for treating cancer - Google Patents
Formulations for treating cancer Download PDFInfo
- Publication number
- WO2024163641A3 WO2024163641A3 PCT/US2024/013812 US2024013812W WO2024163641A3 WO 2024163641 A3 WO2024163641 A3 WO 2024163641A3 US 2024013812 W US2024013812 W US 2024013812W WO 2024163641 A3 WO2024163641 A3 WO 2024163641A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulations
- treating cancer
- cancer
- compositions
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present disclosure relates to methods and compositions for the treatment of cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363482769P | 2023-02-01 | 2023-02-01 | |
| US63/482,769 | 2023-02-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2024163641A2 WO2024163641A2 (en) | 2024-08-08 |
| WO2024163641A3 true WO2024163641A3 (en) | 2024-10-10 |
Family
ID=92147295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2024/013812 Ceased WO2024163641A2 (en) | 2023-02-01 | 2024-01-31 | Formulations for treating cancer |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024163641A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022523073A (en) | 2019-01-29 | 2022-04-21 | フォグホーン セラピューティクス インコーポレイテッド | Compounds and their use |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017223452A1 (en) * | 2016-06-23 | 2017-12-28 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use |
| US20180044335A1 (en) * | 2015-03-05 | 2018-02-15 | Boehringer Ingelheim International Gmbh | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 |
| US20200129532A1 (en) * | 2017-07-24 | 2020-04-30 | Salk Institute For Biological Studies | Use of bromodomain-containing protein 9 antagonists in combination with vitamin d receptor agonists in diabetes treatment |
| US20210230190A1 (en) * | 2020-01-29 | 2021-07-29 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2023283263A1 (en) * | 2021-07-06 | 2023-01-12 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
-
2024
- 2024-01-31 WO PCT/US2024/013812 patent/WO2024163641A2/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180044335A1 (en) * | 2015-03-05 | 2018-02-15 | Boehringer Ingelheim International Gmbh | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 |
| WO2017223452A1 (en) * | 2016-06-23 | 2017-12-28 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use |
| US20200129532A1 (en) * | 2017-07-24 | 2020-04-30 | Salk Institute For Biological Studies | Use of bromodomain-containing protein 9 antagonists in combination with vitamin d receptor agonists in diabetes treatment |
| US20210230190A1 (en) * | 2020-01-29 | 2021-07-29 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2023283263A1 (en) * | 2021-07-06 | 2023-01-12 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024163641A2 (en) | 2024-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019152419A8 (en) | Prc2 inhibitors | |
| MX2024013215A (en) | Compounds for inhibiting kif18a | |
| MX2025013504A (en) | Fused ring kras inhibitors for treating disease | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| AU2020258568A8 (en) | CD73 inhibitors | |
| EP4497438A3 (en) | Tricyclic parp1 inhibitors and uses thereof | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| WO2024006292A3 (en) | Methods of treating cancer | |
| EP4319741A4 (en) | Compositions and methods for the treatment of cancer | |
| WO2023097194A3 (en) | Bicyclic therapeutic compounds and methods of use in the treatment of cancer | |
| WO2023102162A8 (en) | Novel hdac inhibitors and therapeutic use thereof | |
| WO2020231739A3 (en) | Compounds and methods for treating cancer | |
| WO2024163641A3 (en) | Formulations for treating cancer | |
| MX2025013034A (en) | Egfr inhibitors for treating disease | |
| PH12022552489A1 (en) | V delta1+ t cells for the treatment of myeloid malignancies | |
| WO2021178960A3 (en) | Compositions and methods for treatment of cancer | |
| MX2023004881A (en) | Pde9 inhibitors for treating cardiac failure. | |
| EP4110923A4 (en) | Methods and compositions for treatment of apc-deficient cancer | |
| MX2024010401A (en) | Protacs of malt1 | |
| WO2025015149A3 (en) | Methods of treating cancer | |
| WO2024086692A3 (en) | Herpesvirus-induced gene or protein expression and methods for treating neurological disorders | |
| WO2023114847A3 (en) | Compositions and methods for treating disease | |
| WO2023205595A3 (en) | Egfr inhibitors in cancer treatment | |
| WO2023034914A3 (en) | Methods for the prevention and treatment of synucleinopathies | |
| WO2021159062A3 (en) | Compounds, compositions, and methods to treat metabolic disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24750961 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |